{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:39:16Z","timestamp":1792679956437,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AA022448"],"award-info":[{"award-number":["AA022448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009412","name":"USC School of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.neuropharm.2016.09.016","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T17:06:38Z","timestamp":1474045598000},"page":"60-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"PA","title":["Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder"],"prefix":"10.1016","volume":"113","author":[{"given":"Nhat","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Arabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Jakowec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Asatryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl L.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2016.09.016_bib1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.neuropharm.2008.06.044","article-title":"Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors","volume":"55","author":"Asatryan","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.110.167908","article-title":"Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors","volume":"334","author":"Asatryan","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1017\/S1461145713001703","article-title":"Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders","volume":"17","author":"Asatryan","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.toxlet.2004.12.008","article-title":"Does inhibition of P-glycoprotein lead to drug-drug interactions?","volume":"156","author":"Balayssac","year":"2005","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11259-006-3230-7","article-title":"Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle","volume":"30","author":"Baoliang","year":"2006","journal-title":"Vet. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02244901","article-title":"Voluntary consumption of ethanol in 15 inbred mouse strains","volume":"112","author":"Belknap","year":"1993","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10519-009-9298-4","article-title":"Hybrid mice as genetic models of high alcohol consumption","volume":"40","author":"Blednov","year":"2010","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1017\/S1461145712000909","article-title":"Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin","volume":"16","author":"Bortolato","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amepre.2011.06.045","article-title":"Economic Costs of excessive alcohol consumption in the U.S.","volume":"41","author":"Bouchery","year":"2011","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/0091270003257456","article-title":"The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans","volume":"43","author":"Cotreau","year":"2003","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2010.05895.x","article-title":"Preclinical studies of alcohol binge-drinking","volume":"1216","author":"Crabbe","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib12","first-page":"263","article-title":"The role of GABAA receptors in mediating the effects of alcohol in the central nervous system","volume":"28","author":"Davies","year":"2003","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1530-0277.2002.tb02604.x","article-title":"Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent","volume":"26","author":"Davies","year":"2002","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuropharm.2005.03.015","article-title":"Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes","volume":"49","author":"Davies","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0022-3565(24)39005-6","article-title":"Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid A receptor","volume":"295","author":"Dawson","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib16","first-page":"1","article-title":"Ivermectin: does P-glycoprotein play a role in neurotoxicity","volume":"24","author":"Edwards","year":"2003","journal-title":"Filaria J."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2008.03.021","article-title":"Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis","volume":"97","author":"Ford","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2004.02.004","article-title":"The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991\u20131992 and 2001\u20132002","volume":"74","author":"Grant","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002401382731","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/ps.2010.61.4.392","article-title":"Pharmacotherapy of alcohol use disorders in the veterans health administration","volume":"61","author":"Harris","year":"2010","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib21","series-title":"Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data","author":"Harwood","year":"2000"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","article-title":"Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms","volume":"111","author":"Heilig","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2885.2012.01424.x","article-title":"Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin","volume":"36","author":"Janko","year":"2013","journal-title":"J.\u00a0Vet. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/appi.ajp.2010.08101500","article-title":"Medication treatment of different types of alcoholism","volume":"167","author":"Johnson","year":"2010","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/dmd.109.030700","article-title":"Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice","volume":"38","author":"Kiki-Mvouaka","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib27","first-page":"2","article-title":"Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin","volume":"1","author":"Korth-Bradley","year":"2012","journal-title":"Clin. Pharmacol. Drug Deve."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2885.1997.00825.x","article-title":"Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle","volume":"20","author":"Lanusse","year":"1997","journal-title":"J.\u00a0Vet. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejps.2006.10.004","article-title":"Interaction of macrocyclic lactones with P-glycoprotein: structure\u2013affinity relationship","volume":"30","author":"Lespine","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/npp.2009.209","article-title":"CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL\/6J mice independent of the HPA axis","volume":"35","author":"Lowery","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1615\/CritRevNeurobiol.v12.i4.40","article-title":"Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents","volume":"12","author":"McBride","year":"1998","journal-title":"Crit. Rev. Neurbiol."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib33","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.1371\/journal.pntd.0001883","article-title":"Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-\/-) mice and effects on mammalian GABA(A) channel activity","volume":"6","author":"Menez","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib34","doi-asserted-by":"crossref","first-page":"20093","DOI":"10.1073\/pnas.1005554107","article-title":"Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders","volume":"16","author":"Neasta","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","article-title":"Ivermectin: 25 years and still going strong","volume":"31","author":"Omura","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1471-4159.2009.06460.x","article-title":"A\u00a0point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors","volume":"112","author":"Popova","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpddr.2012.04.001","article-title":"Moxidectin and the avermectins: consanguinity but not identity","volume":"2","author":"Prichard","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.physbeh.2004.10.007","article-title":"Evaluation of a simple model of ethanol drinking to intoxication in C57BL\/6J mice","volume":"31","author":"Rhodes","year":"2005","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/acer.13064","article-title":"A\u00a0pilot study of the safety and initial efficacy of ivermectin for the treatment of alcohol use disorder","volume":"40","author":"Roche","year":"2016","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib40","doi-asserted-by":"crossref","first-page":"12556","DOI":"10.1074\/jbc.M011264200","article-title":"Ivermectin, an unconventional agonist of the glycine receptor chloride channel","volume":"276","author":"Shan","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib41","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABAA receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J.\u00a0Bio Chem."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1016094726033","article-title":"Possible anxiolytic effects of ivermectin in rats","volume":"26","author":"Spinosa","year":"2002","journal-title":"Vet. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib43","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","article-title":"Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking","volume":"104","author":"Steensland","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib44","series-title":"Table\u00a02.46B\u2014Alcohol Use, Binge Alcohol Use, and Heavy Alcohol Use in the Past Month among Persons Aged 18 or Older, by Demographic Characteristics: Percentages, 2012 and 2013","author":"Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health (NSDUH)","year":"2013"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/npp.2013.230","article-title":"Repeated binge-like ethanol drinking alters ethanol drinking patterns and depresses striatal GABAergic transmission","volume":"39","author":"Wilcox","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S0031182005008218","article-title":"Glutamate-gated chloride channels and the mode of action of the avermectin\/milbemycin anthelmintics","volume":"131","author":"Wolstenholme","year":"2005","journal-title":"Parasitology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s11064-014-1271-9","article-title":"Contribution of P2X4 receptors to ethanol intake in male C57BL\/6 mice","volume":"39","author":"Wyatt","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/npp.2008.99","article-title":"Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area","volume":"34","author":"Xiao","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib49","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2012.02.062","article-title":"Amino acid residues of both the extracellular and transmembrane domains influence binding of the antiparasitic agent milbemycin to Haemonchus contortus AVR-14B glutamate-gated chloride channels","volume":"419","author":"Yamaguchi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.09.016_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2012.03.014","article-title":"Ivermectin reduces alcohol intake and preference in mice","volume":"63","author":"Yardley","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib51","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/WNR.0000000000000211","article-title":"Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans","volume":"13","author":"Yardley","year":"2014","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.alcohol.2015.03.006","article-title":"Oral delivery of ivermectin using a fast dissolving oral film: implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder","volume":"49","author":"Yardley","year":"2015","journal-title":"Alcohol"},{"key":"10.1016\/j.neuropharm.2016.09.016_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.alcohol.2007.12.006","article-title":"Voluntary ethanol consumption in 22 inbred mouse strains","volume":"42","author":"Yoneyama","year":"2008","journal-title":"Alcohol"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816304002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816304002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:23:32Z","timestamp":1749583412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816304002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":53,"alternative-id":["S0028390816304002"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}